ICMR, Panacea Biotec begin Phase 3 clinical trial of indigenous dengue vaccine, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

The tetravalent dengue vaccine strain (TV003/TV005), initially developed by the National Institutes of Health (NIH) in the USA, has demonstrated promising results in global preclinical and clinical trials. In India, Phase 1 and 2 trials of the vaccine formulation were completed in 2018-19 with positive outcomes, according to Union Health Ministry., The tetravalent dengue vaccine strain (TV003/TV005), initially developed by the National Institutes of Health (NIH) in the USA, has demonstrated promising results in global preclinical and clinical trials. In India, Phase 1 and 2 trials of the vaccine formulation were completed in 2018-19 with positive outcomes, according to Union Health Ministry., , Read More